Preparation of risedronate nanoparticles by solvent evaporation technique

Molecules

Volumn 19, Issue 11, 2014, Pages 17848-17861

  Vaculikova, Eliska ^a,b   Placha, Daniela ^b   Pisarcik, Martin ^c   Peikertova, Pavlina ^b   Dedkova, Katerina ^b   Devinsky, Ferdin ^c   Jampilek, Josef ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b VSB TECHNICAL UNIVERSITY OF OSTRAVA   (Czech Republic)

^c Physics and Informatics   (Slovakia)

Author keywords

Dynamic light scattering; Excipients; Infrared spectroscopy; Nanoparticles; Risedronate sodium; Scanning electron microscopy; Solvent evaporation

Indexed keywords

CARBOXYMETHYLCELLULOSE; CARBOXYMETHYLDEXTRAN; DEXTRAN; DODECYL SULFATE SODIUM; DRUG CARRIER; ETIDRONIC ACID; EXCIPIENT; MACROGOL DERIVATIVE; NANOPARTICLE; POLYSORBATE; RISEDRONIC ACID; SOLVENT;

ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICS; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBOXYMETHYLCELLULOSE SODIUM; DEXTRANS; DRUG CARRIERS; ETIDRONIC ACID; EXCIPIENTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYETHYLENE GLYCOLS; POLYSORBATES; SODIUM DODECYL SULFATE; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84914125454     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191117848     Document Type: Article

References (30)

1. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 239-245.
2. Lipinski, C.A.; Lombardo, F. Experimental and computational approaches to estimated solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.
3. Kerns, E.H.; Li, D. Drug-Like Properties: Concept, Structure Design and Methods; Elsevier: San Diego, CA, USA, 2008.
4. Sivasankar, M.; Kumar, B.P. Role of nanoparticles in drug delivery system. Int. J. Res. Pharm. Biol. Sci. 2010, 1, 41-66.
5. Shaikh, M.S.; Nikita, D. Permeability enhancement techniques for poorly permeable drugs: A review. J. Appl. Pharm. Sci. 2012, 2, 34-39.
6. Onoue, S.; Yamada, S.; Chan, H.K. Nanodrugs: Pharmacokinetics and safety. Int. J. Nanomed. 2014, 9, 1025-1037.
7. Nehoff, H.; Parayath, N.N.; Domanovitch, L.; Taurin, S.; Greish, K. Nanomedicine for drug targeting: Strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 2014, 9, 2539-2555.
8. Delie, F.; Blanco-Prieto, M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 2005, 10, 65-80.
9. Konan, Y.N.; Berton, M.; Gurny, R.; Allemand, E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur. J. Pharm. Sci. 2003, 18, 241-249.
10. Bawa, R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnol. Law Bus. 2008, 5, 135-155.
11. Bawa, R. Nanopharmaceuticals for drug delivery-A review. Drug Deliv. 2009, 3, 122-127.
12. Ezra, A.; Golomb, G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Del. Rev. 2000, 42, 175-195.
13. Aft, R.; Perez, J.R.; Raje, N.; Hirsh, V.; Saad, F. Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. Crit. Rev. Oncol. Hematol. 2012, 82, 233-248.
14. Van Beek, E.R.; Lowik, C.W.; Ebetino, F.H.; Papapoulos, S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 1998, 23, 437-442.
15. MedicineNet. Available online: http://www.medicinenet.com/risedronate/article.htm (accessed on 5 August 2014).
16. TM. Available online: http://osteoporosis.emedtv.com/ (accessed on 5 August 2014).
17. Risedronate: Drug Bank Online-drugbank.ca. Available online: http://www.drugbank.ca/ drugs/DB00884 (accessed on 5 August 2014).
18. Mitchel, D.Y.; Barr, W.H.; Eusebio, R.A.; Stevens, K.A.; Duke, F.P.; Rusell, D.A.; Nesbitt, J.D.; Powell, J.A.; Thompson, G.A. Risedronate pharmacokinetics intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm. Res. 2001, 18, 166-170.
19. Dissette, V.; Bozzi, P.; Bignozzi, C.A.; Dalpiaz, A.; Ferraro, L.; Beggiato, S.; Leo, E.; Vighi, E.; Pasti, L. Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates. Eur. J. Pharm. Sci. 2010, 41, 328-336.
20. Oktabec, Z.; Kos, J.; Mandelova, Z.; Havelkova, L.; Pekarek, T.; Rezacova, A.; Placek, L.; Tkadlecova, M.; Havlicek, J.; Dohnal, J.; et al. Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives. Molecules 2010, 15, 8973-8987.
21. Kos, J.; Pentakova, M.; Oktabec, Z.; Krejcik, L.; Harokova, P., Hruskova, J.; Pekarek, T.; Dammer, O.; Havlicek, J.; Kral, V.; et al. Crystallization products of risedronate with carbohydrates and their substituted derivatives. Molecules 2011, 16, 3740-3760.
22. Jung, I.W.; Han, H.K. Effective mucoadhesive liposomal delivery system for risedronate: Preparation and in vitro/in vivo characterization. Int. J. Nanomed. 2014, 9, 2299-2306.
23. Vaculikova, E.; Grunwaldova, V.; Kral, V.; Dohnal, J.; Jampilek, J. Primary investigation of the preparation of nanoparticles by precipitation. Molecules 2012, 17, 11067-11078.
24. Vaculikova, E.; Grunwaldova, V.; Kral, V.; Dohnal, J.; Jampilek, J. Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. Molecules 2012, 17, 13221-13234.
25. Vaculikova, E.; Placha, D.; Cech-Barabaszova, K.; Jampilek, J. Cimetidine nanoparticles study. Adv. Sci. Eng. Med. 2014, 6, 477-481.
26. Thorat, A.A.; Dalvi, S.V. Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective. Chem. Eng. J. 2012, 181/182, 1-34.
27. U.S. Food and Drug Administration-Generally Recognized as Safe (GRAS). Available online: http://www.fda.gov/food/IngredientspackagingLabeling/GRAS/ (accessed on 5 August 2014).
28. Merkus, H.G. Particle Size Measurements: Fundamentals, Practice, Quality; Springer Science+Business Media B.V.: Dordrecht, The Netherlands, 2009.
29. Win, K.Y.; Feng, S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26, 2713-2722.
30. Malvern Instruments Ltd: Dynamic Light Scattering Common Terms Defined. Available online: http://www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/DLS-Terms-defined-Malvern.pdf (accessed on 5 August 2014).